We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

231 hedge funds and large institutions have $2.61B invested in Axsome Therapeutics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 90 increasing their positions, 54 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 16

75% more call options, than puts

Call options by funds: $106M | Put options by funds: $60.5M

67% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 54

33% more capital invested

Capital invested by funds: $1.97B → $2.61B (+$647M)

17% more funds holding

Funds holding: 197 → 231 (+34)

4.83% more ownership

Funds ownership: 73.31% → 78.14% (+4.8%)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

Holders
231
Holders Change
+34
Holders Change %
+17.26%
% of All Funds
3.63%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
50
Increased
90
Reduced
54
Closed
16
Calls
$106M
Puts
$60.5M
Net Calls
+$45.1M
Net Calls Change
+$22.7M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$73.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$56.4M
3
RI
RTW Investments
New York
+$37.1M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$34M
5
DTC
Deep Track Capital
Connecticut
+$28.3M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$51.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$44.7M
3
Holocene Advisors
Holocene Advisors
New York
-$32.6M
4
Millennium Management
Millennium Management
New York
-$22.4M
5
WP
Woodline Partners
California
-$9.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
201
Clearstead Advisors
Ohio
$97K – – –
QC
202
Quent Capital
New York
$87.2K – – –
HFS
203
Hantz Financial Services
Michigan
$79K – – –
TRCT
204
Tower Research Capital (TRC)
New York
$71.4K +$13.1K +178 +22%
Nisa Investment Advisors
205
Nisa Investment Advisors
Missouri
$65.8K +$6.64K +90 +11%
CI Investments Inc
206
CI Investments Inc
Ontario, Canada
$59K +$60.8K +824 New
CUAMC
207
China Universal Asset Management Company
China
$41K -$1.33K -18 -3%
KTC
208
Kistler-Tiffany Companies
Pennsylvania
$35.9K – – –
KFI
209
Key Financial Inc
Pennsylvania
$32.3K – – –
AAG
210
Armstrong Advisory Group
Massachusetts
$30.4K – – –
HI
211
Harbour Investments
Wisconsin
$26.2K +$22.1K +300 +462%
HNB
212
Huntington National Bank
Ohio
$25.9K +$3.32K +45 +14%
HT
213
Headlands Technologies
Illinois
$23.4K +$24K +325 New
BWA
214
BDO Wealth Advisors
Florida
$21.6K – – –
Fifth Third Bancorp
215
Fifth Third Bancorp
Ohio
$14.4K – – –
Daiwa Securities Group
216
Daiwa Securities Group
Japan
$13K – – –
UB
217
UMB Bank
Missouri
$11.7K – – –
QCG
218
Quadrant Capital Group
Ohio
$10.1K +$369 +5 +4%
First Manhattan
219
First Manhattan
New York
$7.19K – – –
S
220
SignatureFD
Georgia
$5.25K -$1.48K -20 -22%
Barclays
221
Barclays
United Kingdom
$5.25K +$5.38K +73 New
AF
222
Allworth Financial
California
$2.73K +$1.48K +20 +111%
FHA
223
First Horizon Advisors
Tennessee
$2.66K – – –
AWM
224
Atticus Wealth Management
Florida
$1.44K – – –
LF
225
Lee Financial
Texas
$1.15K – – –
6 7 8
9
10

AXSM Hedge Fund Activity: Q2 2023 in Review

231 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2023, worth a combined $2.61B — up 33% from $1.97B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new AXSM positions and 16 closed out — a net gain of 34 holders — while 90 added to existing stakes and 54 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $73.8M. The largest seller was Point72 Asset Management, cutting an estimated $51.8M.

  • 231 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2023, up from 197 in Q1 2023.
  • Funds reported $2.61B of Axsome Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
  • 50 funds opened new Axsome Therapeutics positions in Q2 2023 and 16 closed out, a net change of +34 holders.
  • The largest Axsome Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $73.8M added.
  • The largest Axsome Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $51.8M sold.

Based on aggregated 13F filings for Q2 2023.